Nabi Biopharmaceuticals

  • December 2011
  • -
  • MarketLine

Nabi Biopharmaceuticals - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Features:

- Detailed information on Nabi Biopharmaceuticals required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Nabi Biopharmaceuticals in the form of a SWOT analysis
- An in-depth view of the business model of Nabi Biopharmaceuticals including a breakdown and examination of key business segments
- Intelligence on Nabi Biopharmaceuticals’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Nabi Biopharmaceuticals, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

Nabi Biopharmaceuticals (Nabi) is a biopharmaceutical company focused on the development of vaccines addressing the unmet medical need of nicotine addiction. The company has its operations in the US. It is headquartered in Rockville, Maryland and employed 35 people as of December 2010. The company recorded revenues of $35 million during the financial year ended December 2010 (FY2010), as compared to revenues of $10.5 million in FY2009. The operating loss of the company was $1.2 million during FY2010, as compared to operating loss of $18.0 million in FY2009. The net profit was $0.9 million in FY2010, as compared to net loss of $18.7 million in FY2009.

Reasons to Purchase:

- Gain understanding of Nabi Biopharmaceuticals and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess Nabi Biopharmaceuticals as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers' businesses better
- Stay up to date on Nabi Biopharmaceuticals’s business structure, strategy and prospects

Table Of Contents

Company Snapshot
Nabi Biopharmaceuticals: Company Overview
Nabi Biopharmaceuticals: Overview and Key Facts
Nabi Biopharmaceuticals: Overview
Nabi Biopharmaceuticals: Key Facts
Nabi Biopharmaceuticals: Key Employees
Nabi Biopharmaceuticals: Key Employee Biographies
Nabi Biopharmaceuticals: Major Products and Services
Nabi Biopharmaceuticals: Company History
Nabi Biopharmaceuticals: Locations and Subsidiaries
Nabi Biopharmaceuticals: Key Competitors
Nabi Biopharmaceuticals: Company Analysis
Nabi Biopharmaceuticals: Business Description
Nabi Biopharmaceuticals: SWOT Analysis
Nabi Biopharmaceuticals: SWOT Overview
Nabi Biopharmaceuticals: Strengths
Nabi Biopharmaceuticals: Weaknesses
Nabi Biopharmaceuticals: Opportunities
Nabi Biopharmaceuticals: Threats
Nabi Biopharmaceuticals: Corporate Financial Deals Activity
Nabi Biopharmaceuticals: Financial Deals Overview
Nabi Biopharmaceuticals: Targets and Partners
Nabi Biopharmaceuticals: Top Deals 2007 -YTD*2012
Nabi Biopharmaceuticals: Advisors
Nabi Biopharmaceuticals: Top Financial Advisors
Nabi Biopharmaceuticals: Partnership
Nabi Biopharmaceuticals: Private Equity and Ownership
Nabi Biopharmaceuticals: Recent Developments
Nabi Biopharmaceuticals: News and Events Summary
Nabi Biopharmaceuticals: Contracts
Nabi Biopharmaceuticals: Financial Performance
Nabi Biopharmaceuticals: Regulatory and Legal Events
Nabi Biopharmaceuticals: Research and Development
Nabi Biopharmaceuticals: Strategy and Operations
Appendix
Contact Us
Methodology
Definitions
About Datamonitor

List of Tables

Table 1: Nabi Biopharmaceuticals: Key Facts
Table 2: Nabi Biopharmaceuticals: Key Employees
Table 4: Nabi Biopharmaceuticals: Key Competitors
Table 5: Nabi Biopharmaceuticals: Deal Activity by Deal Type - Volume (2008 - YTD*2012)
Table 6: Nabi Biopharmaceuticals: Targets and Partners
Table 7: Nabi Biopharmaceuticals: Top Deals 2007 -YTD*2012
Table 8: Nabi Biopharmaceuticals: Financial Advisor Ranking by Value (US$m)
Table 9: Nabi Biopharmaceuticals: Partnership Volume and Value Trend (2008 - YTD*2012)
Table 10: Nabi Biopharmaceuticals: Partnership Trend by Deal Type (2008 - YTD*2012)
Table 11: Nabi Biopharmaceuticals: Private Equity and Ownership Volume and Value Trend (2008 - YTD*2012)
Table 12: Nabi Biopharmaceuticals: Private Equity and Ownership Volume by Deal Type (2008 - YTD*2012)
Table 13: Nabi Biopharmaceuticals: News and Events Summary
Table 14: Nabi Biopharmaceuticals: Contracts
Table 15: Nabi Biopharmaceuticals: Financial Performance
Table 16: Nabi Biopharmaceuticals: Regulatory and Legal Events
Table 17: Nabi Biopharmaceuticals: Research and Development
Table 18: Nabi Biopharmaceuticals: Strategy and Operations

List of Figures

Figure 1: Nabi Biopharmaceuticals: Deal Activity by Deal Type - Volume (2008 - YTD*2012)
Figure 2: Nabi Biopharmaceuticals: Partnership Volume and Value Trend (2008 - YTD*2012)
Figure 3: Nabi Biopharmaceuticals: Partnership Trend by Deal Type (2008 - YTD*2012)
Figure 4: Nabi Biopharmaceuticals: Private Equity and Ownership Volume and Value Trend (2008 - YTD*2012)
Figure 5: Nabi Biopharmaceuticals: Private Equity and Ownership Volume by Deal Type (2008 - YTD*2012)

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

World Biopharmaceutical: Growth Hormone Deficiency – Pipeline Review, H1 2012

World Biopharmaceutical: Growth Hormone Deficiency – Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • March 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Growth Hormone Deficiency, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...

Drug Discovery and Development in United States: Ipsen S.A. – Product Pipeline Review – H2 2011

Drug Discovery and Development in United States: Ipsen S.A. – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • May 2014
  • by Global Markets Direct

. - Product Pipeline Review - H2 2011” provides a detailed overview on the Ipsen S.A.’s research and development focus. The report includes data on current developmental pipeline, complete with latest ...

Drug Discovery and Development Industry: F. Hoffmann-La Roche Ltd. – Product Pipeline Review – Q4 2010

Drug Discovery and Development Industry: F. Hoffmann-La Roche Ltd. – Product Pipeline Review – Q4 2010

  • $ 1 500
  • Company report
  • May 2014
  • by Global Markets Direct

Hoffmann-La Roche Ltd. - Product Pipeline Review - Q4 2010” provides a detailed overview on the firm ’s research and development focus. The report includes data on current developmental pipeline, complete ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.